2. Signaling Pathways
  3. Others
  4. Drug Derivative

Drug Derivative

Drug derivative

Drug derivatives are derived from parent compounds. They replace or add atoms and groups through chemical reactions to optimize the various properties of the parent compound and reduce side effects. The application of drug derivatives provides a diverse compound library for drug research and development and accelerates the discovery of new drugs. For example, urea derivatives Glibenclamide can prolong the blood sugar-lowering effect of anti-diabetic drugs.

Drug Derivative Related Products (3806):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W005627
    Linoleyl alcohol
    		99.84%
    Linoleyl alcohol, a structural analog of Linoleic acid with no a-carboxyl group, is a fatty alcohol.
    Linoleyl alcohol
  • HY-W007708
    3-Furanmethanol
    		99.92%
    3-Furanmethanol, a volatile furan compound, can be detected in malt beverages fermented with Bifidobacterium breve. 3-Furanmethanol exhibits roasty, popcorn-like flavors.
    3-Furanmethanol
  • HY-15642
    TD-198946
    		99.17%
    TD-198946, a thienoindazole derivative, is a potent chondrogenic agent.
    TD-198946
  • HY-111652
    S-Gboxin
    		99.62%
    S-Gboxin is a functional analog of the oxidative phosphorylation (OXPHOS) inhibitor Gboxin and has antitumor activity. S-Gboxin inhibits the growth of mouse and human glioblastoma with an IC50 of 470 nM. S-Gboxin has antitumor activity.
    S-Gboxin
  • HY-33893
    Indole-3-methanamine
    		99.14%
    Indole-3-methanamine is an indole derivative, stress-related metabolite, and also a biosynthetic precursor of Gramine (HY-N0166). The accumulation level of Indole-3-methanamine increases in susceptible barley varieties infected with Bipolaris sorokiniana. Indole-3-methanamine can be used in studies related to barley spot blotch.
    Indole-3-methanamine
  • HY-P4486
    H-Pro-Gly-Pro-OH
    		99.79%
    H-Pro-Gly-Pro-OH is a collagen-derived matrikine that has classically been described as a neutrophil chemoattractant. H-Pro-Gly-Pro-OH is perfectly positioned to focus neutrophils on the site required and direct a localized repair response. H-Pro-Gly-Pro-OH activates the transcription of neurotrophins and their receptor genes after cerebral ischemia.
    H-Pro-Gly-Pro-OH
  • HY-146695
    S100P-IN-1
    		99.81%
    S100P-IN-1 (Compound 4) is a S100P inhibitor with an IC50 of 22.7 nM. S100P-IN-1 shows anti-metastatic effects on pancreatic cancer cells.
    S100P-IN-1
  • HY-112132
    Palmitodiolein
    		99.81%
    Palmitodiolein (Triglyceride POO) is a triacylglycerol which is present in vegetable oils.
    Palmitodiolein
  • HY-158998
    ALKBH1-IN-2
    		99.16%
    ALKBH1-IN-2 (Compound 16) is a derivative of ALKBH1-IN-1 (HY-163385). ALKBH1-IN-2 is an ALKBH1 inhibitor. ALKBH1-IN-2 can modulate the 6mA levels.
    ALKBH1-IN-2
  • HY-B1785
    5-Sulfosalicylic acid
    		98.74%
    5-Sulfosalicylic acid is a sulfonated salicylic acid derivative. 5-Sulfosalicylic acid is effective against the breast cancer cell lines, with less toxicity. 5-Sulfosalicylic acid has antioxidant activities.
    5-Sulfosalicylic acid
  • HY-45609
    L-Cysteine S-sulfate sodium hydrate
    		98.0%
    L-Cysteine S-sulfate sodium hydrate is an S-sulfated derivative of L-cysteine (HY-Y0337). L-Cysteine S-sulfate sodium hydrate is the substrate for cystine lyase, it can be used in mass spectrometry and chromatography analyses.
    L-Cysteine S-sulfate sodium hydrate
  • HY-W506071
    3,7-Dimethyluric acid
    		99.95%
    3,7-Dimethyluric acid is a methyl derivative of uric acid.
    3,7-Dimethyluric acid
  • HY-Z11724
    Semaglutide Main Chain (9-37)
    		99.62%
    Semaglutide Main Chain (9-37) is a peptide starting material in the synthesis of semaglutide (HY-114118).
    Semaglutide Main Chain (9-37)
  • HY-13769A
    TPT-260 Dihydrochloride
    		98.0%
    TPT-260 Dihydrochloride (NSC55712), a thiophene thiourea derivative, is a retromer complex stabilizer against thermal denaturation (Kd = ~5 µM). TPT-260 Dihydrochloride increases the levels of retromer proteins, shifts amyloid-precursor protein (APP) away from the endosome, and decreases the pathogenic processing of APP. TPT-260 Dihydrochloride inhibits TLR4 upregulation, IKKβ phosphorylation, NF-κB p65 nuclear translocation, and NLRP3 inflammasome formation. TPT-260 Dihydrochloride improves retromer-mediated cargo trafficking, reduces brain infarct area, and decreases amyloid plaque deposition. TPT-260 Dihydrochloride exhibits minimal cytotoxicity to primary microglia at tested concentrations. TPT-260 Dihydrochloride can be used for the research of inflammatory bowel disease, ischemic stroke and Alzheimer's disease.
    TPT-260 Dihydrochloride
  • HY-111178
    Lauflumide
    		99.89%
    Lauflumide (BisfluoroModafinil) is the common alternative of modafinil. Modafinil is commonly prescribed for the research narcolepsy. Lauflumide has the potential for cognitive enhancing.
    Lauflumide
  • HY-B2102
    Oxyphenisatine
    		98.12%
    Oxyphenisatine (Oxyphenisatin) is a laxative. Oxyphenisatin acetate is the pro-agent of oxyphenisatin with anticancer activity.
    Oxyphenisatine
  • HY-108767
    Insulin aspart
    Insulin aspart (B28Asp) is a rapid-acting h-Insulin (HY-P0035) analog. Insulin aspart induces a faster hypoglycemic effect. Insulin aspart can be used in diabetes-related research.
    Insulin aspart
  • HY-128995A
    Glycyl-Exatecan TFA
    		98.73%
    Glycyl-Exatecan TFA (Glycyl-DX-8951 TFA), a derivative of Exatecan (HY-13631), is an anticancer agent. Glycyl-Exatecan TFA has significantly antitumor activity. Glycyl-Exatecan TFA can be used for cancers like solid tumors research.
    Glycyl-Exatecan TFA
  • HY-133513
    (±)-H3RESCA-TFP
    (±)-H3RESCA-TFP ((±)-H3L28) is a tetrafluorophenyl ester derivative of restrained complexing agent (RESCA). (±)-H3RESCA-TFP can be used to conjugate the chelator with a biomolecule via amine coupling (e.g., N terminus and/or the ε-amino groups of lysine).
    (±)-H3RESCA-TFP
  • HY-P3226
    JB-1
    		99.63%
    JB-1, an IGF-I analog, is a selective IGF-I receptor inhibitor that does not interact with IGF-II. JB-1 competes with IGF-I for binding to IGF-1R and blocks receptor autophosphorylation. JB-1 increases the level of sVEGFR-1. JB-1 normalizes retinal abnormalities, including reducing retinal neovascularization. JB-1 is applicable to studies related to oxygen-induced retinopathy.
    JB-1